Organization
FDA/CDER
4 abstracts
Abstract
Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.Org: FDA/CDER, U.S. Food and Drug Administration, US Food and Drug Administration, Oncology Center of Excellence, Office of New Drugs,
Abstract
Trends in new and persistent opioid use in older adults with cancer.Org: Yale School of Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New Haven, CT, Cancer Outcomes, Public Policy and Effectiveness Research Center, Public Policy and Effectiveness Research (COPPER) Center,
Abstract
FDA analysis of treatment efficacy based on etiology of hepatocellular carcinoma.Org: US Food and Drug Administration, Silver Spring, MD, FDA/CDER, Center for Drug Evaluation and Research, U.S. Food and Drug Administration,
Abstract
FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials.Org: US Food and Drug Administration, U.S. Food and Drug Administration, FDA/CDER, Food and Drug Administration, Oncology Center of Excellence,